Showing results (141-150 of 220) with videos related to
Sort By:
Pageof 22
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.Journal of the Neurological Sciences|September 19, 2021
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registryRachel Kenney, Mengling Liu, Sachi Patil, et al.Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.Journal of Neurology, Neurosurgery, and Psychiatry|July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 yearsJodie I Roberts, Sifat Sharmin, Dana Horakova, et al.Annals of Neurology|April 26, 2017
Prognostic indicators in pediatric clinically isolated syndromePietro Iaffaldano, Marta Simone, Giuseppe Lucisano, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 3, 2026
Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase studyCassie Nesbitt, Paul Sanfilippo, Chao Zhu, et al.Annals of Clinical and Translational Neurology|May 23, 2015
Predictors of disability worsening in clinically isolated syndromeVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.Multiple Sclerosis and Related Disorders|December 27, 2019
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorderAmy Kunchok, Charles Malpas, Petra Nytrova, et al.Pageof 22